BioXcel Presents Data on Potential Therapy at Prostate Cancer Foundation Retreat in D.C.

BioXcel Presents Data on Potential Therapy at Prostate Cancer Foundation Retreat in D.C.
BioXcel Therapeutics’ immuno-oncology candidate BXCL701 was shown to enhance the anti-tumor effects of immune checkpoint inhibitors in prostate models, according to an Oct. 5 poster session at the 24th Annual Prostate Cancer Foundation Scientific Retreat in Washington, D.C. The company reported recent findings from multiple studies showing that BXCL701 — a dipeptidyl peptidases (DPP) inhibitor — could inhibit tumor growth by increasing pro-inflammatory protein levels and immune-cell modulation in a series of cancer models. The drug achieves this effect by inhibiting DPP8/9 and Fibroblast Activator Protein (FAP), which affect neuroendocrine prostate cancer (NEPC) at different stages of disease progression. The poster, “Synergy Between [BXCL701], a DPP Inhibitor, and Immune Checkpoint Inhibitors Discovered Using AI and Big Data Analytics,” was presented by Vince O’Neill, chief medical officer of BioXcel, which is based in Branford, Connecticut. “We had previously identified the tremendous potential of BXCL701 as a tumor inhibitory agent in castration-resistant prostate cancer (CRPC)," O’Neill stated in a press release. "Mechanistic studies suggest that BXCL701 also has potential to induce anti-tumor effect in NEPC, an aggressive tumor type observed in roughly 20-30% of patients treated with androgen inhibitors, Zytiga and Xtandi (ADT).” O'Neill
Subscribe or to access all post and page content.